Kelly Lacob: Co-Founder and CEO of Xella Health
In this episode, Nora sits down with Kelly Lacob, Co-Founder and CEO of Xella Health. Kelly is a healthcare technologist, product designer, and systems thinker who has spent her career translating early-stage frontier science into scalable products for traditionally underserved patients. Trained at Stanford and Johns Hopkins in human biology, bioengineering, and business, Kelly previously led product design for the first CRISPR-powered diagnostic platform at Mammoth Biosciences. She also led the development and launch of the first FDA-cleared point-of-care and at-home PCR test at Visby Medical, which helped power early COVID-19 response efforts.
Today at Xella Health, Kelly is building an intelligence layer for women's biology. Driven by a deeply personal mission after watching the healthcare system fail her mother during a battle with late-stage ovarian cancer, Kelly is applying multi-omic testing and AI to shift care from reactive to proactive. Backed by over $4.7 million in angel and pre-seed funding and a waitlist of over 15,000 women, Xella Health is stepping out of the diagnostic dark age by decoding the XX chromosome directly rather than retrofitting tools built for male baselines.
This conversation is about the intersection of frontier science and digital health, the critical gap between reactive care and proactive longevity, and what it takes to build a comprehensive platform for female biology so that precision medicine is accessible to the everyday woman.
Key Topics:
How Kelly's experience leading product design for pioneering CRISPR and rapid PCR platforms prepared her to architect a comprehensive diagnostics ecosystem for women.
Moving past a healthcare system built on male biology baselines to create an intelligence layer specifically engineered for female biology.
How Xella is using AI to map the complex, dynamic relationships between different biomarkers over time, replacing the traditional medical approach of looking at health metrics in isolated silos.
Replacing guesswork and clinical dismissal with root-cause clarity by layering hormonal, metabolic, genetic, and biomarker data.
Why thousands of women are eagerly seeking out a platform like Xella right now, driven by a deep exhaustion with a fragmented healthcare system that forces them to stitch together their own answers across disjointed specialists.
Inside the innovation behind Xella's upcoming menstrual fluid kit, which utilizes genetic information, methylation data, and mRNA expression to screen for conditions like endometriosis while mapping fertility metrics.
Why data alone isn't enough, and how Xella is prioritizing the post-diagnostic journey by pairing longitudinal clinical data directly with telehealth support to guide women from insight to actual action.
